Welcome to our dedicated page for Medicinova news (Ticker: MNOV), a resource for investors and traders seeking the latest updates and insights on Medicinova stock.
MediciNova, Inc. develops small-molecule therapeutics for inflammatory, fibrotic, and neurodegenerative diseases. The company's recurring updates center on MN-166, or ibudilast, and MN-001, or tipelukast, including programs involving amyotrophic lateral sclerosis, degenerative cervical myelopathy, progressive multiple sclerosis, chemotherapy-induced peripheral neuropathy, Long COVID, substance dependence, non-alcoholic fatty liver disease, hypertriglyceridemia, and idiopathic pulmonary fibrosis.
MediciNova news also covers clinical-trial progress, expanded-access activity, investigator-sponsored research, peer-reviewed translational studies, scientific and regulatory advisory matters, and corporate updates connected to its Nasdaq-listed common stock and Tokyo Stock Exchange listing.
MediciNova (NASDAQ:MNOV) completed last patient last visit in its Phase 2 MN-001-NATG-202 trial of MN-001 (tipelukast) for hypertriglyceridemia and NAFLD associated with type 2 diabetes.
The multicenter, randomized, double-blind, placebo-controlled study compares 500 mg/day MN-001 versus placebo over 24 weeks, with top-line data expected in Q3 2026.
MediciNova (NASDAQ: MNOV) announced a peer‑reviewed study (Cancer Research, Mar 2026) identifying a MIF–CD74 vulnerability in brain metastasis and showing that the brain‑penetrant small molecule ibudilast (MN‑166) can inhibit this pathway in preclinical models.
The study reports reduced metastatic progression with MIF–CD74 inhibition, identification of secreted MIF detectable in cerebrospinal fluid as a candidate biomarker, transcriptomic signatures tied to response, and planned collaboration with CNIO to advance translational clinical research.
MediciNova (NASDAQ: MNOV) will participate in the 38th Annual ROTH Conference March 22–24, 2026 at The Ritz-Carlton, Dana Point, CA.
President & CEO Yuichi Iwaki, M.D., Ph.D., and Chief Business Officer David H. Crean, Ph.D., will hold in-person one-on-one and small group meetings to provide company updates; investors should contact ROTH representatives to arrange meetings.
MediciNova (NASDAQ:MNOV) announced that as of January 2026, 100 patients have been enrolled in the NIH‑funded SEANOBI Expanded‑Access Program (EAP) evaluating MN‑166 (ibudilast) in ALS, representing 50% of the planned 200 enrollment across 12 activated US sites. The program is supported by a $22 million NINDS grant under ACT for ALS and will generate real‑world biomarker and clinical outcome data alongside the COMBAT‑ALS Phase 2b/3 randomized trial (234 patients enrolled; topline expected by end of 2026).
MediciNova (NASDAQ:MNOV) CEO Yuichi Iwaki delivered a New Year letter on Jan 6, 2026 outlining 2025 clinical progress and 2026 priorities.
Clinical highlights: enrollment completed in three trials—COMBAT‑ALS (MN‑166) completed enrollment Sept 2025 with top‑line results expected by year‑end; OXTOX Phase 2b completed enrollment Dec 2025; MN‑001 Phase 2 enrollment completed Nov 2025 with top‑line data anticipated summer 2026. An Expanded Access Program for ALS launched March 2025 supported by a $22 million NIH grant; as of Dec 15, 2025 there were 12 U.S. sites and 87 patients enrolled.
The company says 2026 will be pivotal as it prepares for potential regulatory submission if COMBAT‑ALS results are positive.
MediciNova (NASDAQ:MNOV) announced completion of patient enrollment in the randomized, placebo-controlled Phase 2 OXTOX study evaluating MN-166 (ibudilast) to prevent chemotherapy-induced peripheral neuropathy in metastatic colorectal cancer.
A total of 100 patients were randomized across two arms at 11 clinical sites in Australia. Patient recruitment is closed; participants continue chemotherapy with assigned study drug until disease progression or unacceptable toxicity. The study will conclude when the final patient reaches six months post-chemotherapy. Top-line data are anticipated later in 2026, though no exact completion date is provided.
MediciNova (NASDAQ:MNOV) reported an update from the COMBAT-ALS Phase 2b/3 trial of MN-166 (ibudilast) presented at the 36th International Symposium on ALS/MND (Dec 5–7, 2025).
Key facts: 234 participants randomized, enrollment completed Sept 2025. Baseline metrics: mean age 60.6, mean ALSFRS-R 40.6, mean disease duration 12.5 months. Sex split: 36.8% female, 63.2% male. Racial mix: Caucasian 90.2%, Asian 5.1%.
The company noted COVID-19–related enrollment challenges, is offering continued access via FDA individual expanded access, and cited FDA Orphan Drug and Fast Track designations and European orphan designation. Top-line data are anticipated by end of 2026.
MediciNova (MNOV) reported a peer-reviewed publication showing MN-002, the primary metabolite of MN-001, increases cholesterol efflux by upregulating ABCA1 and ABCG1 in macrophages, a mechanism tied to Reverse Cholesterol Transport.
The company completed patient enrollment in its Phase 2 MN-001-NATG-202 randomized, double-blind, placebo-controlled trial in hypertriglyceridemia and NAFLD due to T2DM; top-line results are expected by summer 2026. Management says the mechanistic data reinforce prior clinical lipid-profile observations and will inform next steps toward advancing MN-001 as a potential first-in-class therapy for metabolic and cardiovascular disease.
MediciNova (NASDAQ:MNOV) announced on November 18, 2025 the appointment of Dr. Christopher D. Breder, MD, PhD as Clinical and Regulatory Advisor. Dr. Breder will provide strategic guidance for MediciNova’s drug development programs and will lead the Scientific Advisory Board upon its formation.
Dr. Breder brings over two decades of regulatory and clinical experience, including more than a decade at the FDA as Medical Officer and Lead Medical Officer, involvement in NDA review and safety analysis training, and participation in reviews and initial approvals for therapies targeting ALS, myasthenia gravis, and Duchenne muscular dystrophy. He holds an MD and PhD from the University of Chicago and completed clinical training at Johns Hopkins Hospital.
MediciNova (NASDAQ:MNOV) announced on November 6, 2025 that it won the Contract Research and Development Innovation Award at the Fifth Annual BioTech Breakthrough Awards.
The award recognizes MediciNova's work advancing MN-166 (ibudilast), its lead small-molecule candidate in development for multiple neurological diseases including ALS. The company noted ongoing progress in the Phase 2/3 COMBAT-ALS trial and said the recognition highlights its focus on neuroinflammation modulation and neuroprotection as a potential disease-modifying approach.